Compare NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) (NWG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) vs TG Therapeutics Inc — how do they compare? NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) trades at $17.13 (market cap $66.98B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) is far larger — about 8.2× TG Therapeutics Inc's market cap, and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) pays a 5.5% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) for 1 Days and TG Therapeutics Inc for 16 Days on average.
| NWG | TGTX | |
|---|---|---|
Market Cap | $66.98B | $8.16B |
Volume | 5,259,060 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $19.42 | $59.06 |
52-Week Low | $13.89 | $26.94 |
Typical Hold Time | 1 Days | 16 Days |
Enterprise Value | $140.55B | $8.37B |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% on the day, amid a bearish technical signal despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS misses and a negative net cash flow of $100.70M in 2025 highlight operational challenges. Positive news includes BRIUMVI capturing significant market share and institutional buying interest.
The outlook is mixed; robust analyst consensus (84.62% buy ratings) and a $80.50 price target suggest upside, but risks include ongoing litigation, earnings volatility, and high valuation multiples. Key catalysts are subcutaneous BRIUMVI data and potential acquisition interest, though execution risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares)
NatWest Group is a UK banking company serving personal, business, and institutional customers. Its services include deposits, lending, payments, and wealth management.
Read more on NWG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
